Immunosuppression in pediatric liver transplantation: Are little people different?

Liver Transplantation

Volumn 17, Issue SUPPL. 3, 2011, Pages

  Dhawan, Anil ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; BODY COMPOSITION; CAUSE OF DEATH; CHILDHOOD MORTALITY; CYTOMEGALOVIRUS INFECTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG OXIDATION; EPSTEIN BARR VIRUS INFECTION; GASTROINTESTINAL ABSORPTION; HUMAN; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS COMPLICATION; LIVER TRANSPLANTATION; MULTICENTER STUDY (TOPIC); PEDIATRIC SURGERY; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; RECURRENT INFECTION; ROUX Y ANASTOMOSIS; VIRUS HEPATITIS; ADULT; AGE; CHILD; GRAFT REJECTION; IMMUNOLOGY; LIVER FAILURE; PEDIATRICS;

ADULT; AGE FACTORS; CHILD; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER FAILURE; LIVER TRANSPLANTATION; PEDIATRICS;

EID: 84857150253     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22422     Document Type: Article

References (54)

1. Halpren SA. American Pediatrics: The Social Dynamics of Professionalism, 1880-1980. Berkeley, CA: University of California Press; 1988: 52.
2. Marfo K, Altshuler J, Lu A. Tacrolimus pharmacokinetic and pharmacogenomic differences between adults and pediatric solid organ transplant recipients. Pharmaceutics 2010;2: 291-299.
3. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology- drug disposition, action, and therapy in infants and children. N Engl J Med 2003;349: 1157-1167.
4. Siber GR, Echeverria P, Smith AL, Paisley JW, Smith DH. Pharmacokinetics of gentamicin in children and adults. J Infect Dis 1975;132: 637-651.
5. Takahashi H, Ishikawa S, Nomoto S, Nishigaki Y, Ando F, Kashima T, et al. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin Pharmacol Ther 2000;68: 541-555.
6. Sharer JE, Wrighton SA. Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine. Drug Metab Dispos 1996;24: 487-494.
7. van den Anker JN, Schoemaker RC, Hop WC, van der Heijden BJ, Weber A, Sauer PJ, et al. Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age. Clin Pharmacol Ther 1995;58: 650-659.
8. Arant BS Jr. Developmental patterns of renal functional maturation compared in the human neonate. J Pediatr 1978;92: 705-712.
9. Marshall JD, Kearns GL. Developmental pharmacodynamics of cyclosporine. Clin Pharmacol Ther 1999;66: 66-75.
10. Tzakis AG, Reyes J, Todo S, Green M, Ohya T, Jain A, et al. FK 506 versus cyclosporine in pediatric liver transplantation. Transplant Proc 1991;23: 3010-3015.
11. Jain A, Mazariegos G, Kashyap R, Green M, Gronsky C, Starzl TE, et al. Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation. Transplantation 2000;70: 617-625.
12. Trompeter R, Filler G, Webb NJ, Watson AR, Milford DV, Tyden G, et al. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr Nephrol 2002;17: 141-149.
13. National Institute for Health and Clinical Excellence. Immunosuppressive therapy for renal transplantation in children and adolescents. http: //guidance.nice.org.uk/ TA99. Published April 2006. Accessed August 2011.
14. Iwatsuki S, Shaw BW Jr, Starzl TE. Liver transplantation for biliary atresia. World J Surg 1984;8: 51-56.
15. Aw MM, Verma A, Rela M, Heaton N, Mieli-Vergani G, Dhawan A. Long-term outcome of mycophenolate mofetil rescue therapy for resistant acute allograft rejection in pediatric liver transplant recipients. Liver Transpl 2008; 14: 1303-1308.
16. Chardot C, Nicoluzzi JE, Janssen M, Sokal E, Lerut J, Otte JB, Reding R. Use of mycophenolate mofetil as rescue therapy after pediatric liver transplantation. Transplantation 2001;71: 224-229.
17. Sindhi R, Webber S, Venkataramanan R, McGhee W, Phillips S, Smith A, et al. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. Transplantation 2001;72: 851-855.
18. Nayyar NS, McGhee W, Martin D, Sindhi R, Soltys K, Bond G, Mazariegos GV. Intestinal transplantation in children: a review of immunotherapy regimens. Paediatr Drugs 2011;13: 149-159.
19. Ganschow R, Broering DC, Stuerenburg I, Rogiers X, Hellwege HH, Burdelski M. First experience with basiliximab in pediatric liver graft recipients. Pediatr Transplant 2001;5: 353-358.
20. Aw MM, Taylor RM, Verma A, Parke A, Baker AJ, Hadzic D, et al. Basiliximab (Simulect) for the treatment of steroid- resistant rejection in pediatric liver transplant recipients: a preliminary experience. Transplantation 2003; 75: 796-799.
21. Cooney GF, Habucky K, Hoppu K. Cyclosporin pharmacokinetics in paediatric transplant recipients. Clin Pharmacokinet 1997;32: 481-495.
22. Trull AK, Tan KK, Tan L, Alexander GJ, Jamieson NV. Absorption of cyclosporine from conventional and new microemulsion oral formulations in liver transplant recipients with external biliary diversion. Br J Clin Pharmacol 1995;39: 627-631.
23. Pescovitz MD, Puente JG, Jindal RM, Fitzgerald J, Chong SK, Milgrom ML, et al. Improved absorption of cyclosporine for microemulsion in a pediatric liver transplant recipient with cystic fibrosis. Transplantation 1996;61: 331-333.
24. Filler G, Bendrick-Peart J, Christians U. Pharmacokinetics of mycophenolate mofetil and sirolimus in children. Ther Drug Monit 2008;30: 138-142.
25. Filler G. Value of therapeutic drug monitoring of MMF therapy in pediatric transplantation. Pediatr Transplant 2006;10: 707-711.
26. Gummert JF, Ikonen T, Morris RE. Newer immunosuppressive drugs: a review. J Am Soc Nephrol 1999;10: 1366-1380.
27. Mukherjee S, Mukherjee U. A comprehensive review of immunosuppression used for liver transplantation. J Transplant 2009;2009: 701464.
28. Vincenti F. The role of newer monoclonial antibodies in renal transplantation. Transplant Proc 2001;33: 1000-1001.
29. Church AC. Clinical advances in therapies targeting the interleukin-2 receptor. QJM 2003;96: 91-102.
30. Urbach AH, Gartner JC, Malatack JJ, Zitelli BJ, Iwatsuki S, Shaw BW, Starzl TE. Linear growth following pediatric liver transplantation. Am J Dis Child 1987; 141: 547-549.
31. Spolidoro JV, Berquist WE, Pehlivanoglu E, Busuttil R, Saluski I, Vargas J, Ament ME. Growth cceleration in children after orthotopic liver transplantation. J Pediatr 1988;112: 41-44.
32. Codoner-Franch P, Bernard O, Alvarez F. Long-term follow-up of growth in height after successful liver transplantation. J Pediatr 1994;124: 368-373.
33. Viner RM, Forton JT, Cole TJ, Clark IH, Noble-Jamieson G, Barnes ND. Growth of long-term survivors of liver transplantation. Arch Dis Child 1999;80: 235-240.
34. Rodeck B, Melter M, Hoyer PF, Ringe B, Brodehl J. Growth in long-term survivors after orthotopic liver transplantation in childhood. Transplant Proc 1994;26: 165-166.
35. Holt RI, Broide E, Buchanan CR, Miell JP, Baker AJ, Mowat AP, Mieli-Vergani G. Orthotopic liver transplantation reverses the adverse nutritional changes of end-stage liver disease in children.AmJ Clin Nutr 1997;65: 534-542.
36. Gras JM, Gerkens S, Beguin C, Janssen M, Smets F, Otte JB, et al. Steroid-free, tacrolimus-basiliximab immunosuppression in pediatric liver transplantation: clinical and pharmacoeconomic study in 50 children. Liver Transpl 2008;14: 469-477.
37. Quirk P, Owens P, Moyse K, Chin S, Wall C, Ballard J, Shepherd R. Insulin-like growth factors I and II are reduced in plasma from growth retarded children with chronic liver disease. Growth Regul 1994;4: 35-38.
38. Bucuvalas JC, Cutfield W, Horn J, Sperling MA, Heubi JE, Campaigne B, Chernausek SD. Resistance to the growth-promoting and metabolic effects of growth hormone in children with chronic liver disease. J Pediatr 1990;117: 397-402.
39. Chin SE, Shepherd RW, Thomas BJ, Cleghorn GJ, Patrick MK, Wilcox JA, et al. Nutritional support in children with end-stage liver disease: a randomized crossover trial of a branched-chain amino acid supplement. Am J Clin Nutr 1992;56: 158-163.
40. Alonso EM, Shepherd R, Martz KL, Yin W, Anand R; for SPLIT Research Group. Linear growth patterns in prepubertal children following liver transplantation. Am J Transplant 2009;9: 1389-1397.
41. Allen U, Hébert D, Moore D, Dror Y, Wasfy S; for Canadian PTLD Survey Group-1998. Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplant recipients, 1988-97: a Canadian multi-centre experience. Pediatr Transplant 2001;5: 198-203.
42. Dhawan A, Muiesan P. Pediatric liver transplantation. Acta Paediatr Jpn 1998;40: 525-529.
43. Ho M. Infection and organ transplantation. In: Gelman S, ed. Anesthesia and Organ Transplantation. Philadelphia, PA: WB Saunders; 1987: 49-60.
44. Nalesnik MA, Makowka L, Starzl TE. The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Probl Surg 1988;25: 367-472.
45. Farmer DG, McDiarmid SV, Yersiz H, Cortina G, Amersi F, Vargas J, et al. Outcome after intestinal transplantation: results from one center's 9-year experience. Arch Surg 2001;136: 1027-1031.
46. Verma A, Wade JJ. Immunization issues before and after solid organ transplantation in children. Pediatr Transplant 2006;10: 536-548.
47. Campbell AL, Herold BC. Immunization of pediatric solid-organ transplantation candidates: immunizations in transplant candidates. Pediatr Transplant 2005;9: 652-661.
48. Burroughs M, Moscona A. Immunization of pediatric solid organ transplant candidates and recipients. Clin Infect Dis 2000;30: 857-869.
49. Blumberg EA, Fitzpatrick J, Stutman PC, Hayden FG, Brozena SC. Safety of influenza vaccine in heart transplant recipients. J Heart Lung Transplant 1998;17: 1075-1080.
50. Shepherd RW, Turmelle Y, Nadler M, Lowell JA, Narkewicz MR, McDiarmid SV, et al.; for SPLIT Research Group. Risk factors for rejection and infection in pediatric liver transplantation. Am J Transplant 2008;8: 396-403.
51. D'Antiga L, Dhawan A, Portmann B, Francavilla R, Rela M, Heaton N, Mieli-Vergani G. Late cellular rejection in paediatric liver transplantation: aetiology and outcome. Transplantation 2002;73: 80-84.
52. Falkenstein K, Flynn L, Kirkpatrick B, Casa-Melley A, Dunn S. Non-compliance in children post-liver transplant. Who are the culprits? Pediatr Transplant 2004;8: 233-236.
53. Annunziato RA, Emre S, Shneider BL, Dugan CA, Aytaman Y, McKay MM, Shemesh E. Transitioning health care responsibility from caregivers to patient: a pilot study aiming to facilitate medication adherence during this process. Pediatr Transplant 2008;12: 309-315.
54. Fredericks EM. Nonadherence and the transition to adulthood. Liver Transpl 2009;15(suppl 2): S63-S69.